Skip to content

Arena Pharma started at buy by Cantor

June 20, 2017

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a report issued on Thursday. The brokerage set an “overweight” rating and a $4.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 205.34% from the company’s previous close.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: